Indeed, wedelolactone could activate PRC2 downstream tumor suppression genes such as DAB2IP, ADRB2, CDKN2A and GADD45A (Figure 3A), thus it serves as a mechanism for its inhibition on PRC2-dependent cancer cells. The gene discussed is CDKN2A; the disease is neoplasm.